Direxion Daily Energy Bear 2X Shares
ERY
iShares US Home Construction ETF
ITB
SPDR S&P Homebuilders ETF
XHB
4
Direxion Daily Financial Bull 3X Shares ETF
FAS
5
iShares Biotechnology ETF
IBB
US Stock MarketDetailed Quotes
Zenas BioPharma (ZBIO)
- 21.550
- +1.345+6.66%
Trading Jun 24 12:03 ET
1.36BMarket Cap-2.37P/E (TTM)
21.760High20.128Low164.18KVolume20.230Open20.205Prev Close3.44MTurnover0.41%Turnover RatioLossP/E (Static)63.13MShares44.60052wk High4.05P/B858.59MFloat Cap8.91052wk Low--Dividend TTM39.84MShs Float44.600Historical High--Div Yield TTM8.08%Range %5.830Historical Low20.940Avg Price1Lot Size
ZBIO Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
ZBIO Orderflow
Unit: --
ZBIO Orderflow Trend
IntradayDayWeekMonth
No Data
Zenas BioPharma (ZBIO) News
Bullish Zenas BioPharma Insiders Loaded Up On US$5.27m Of Stock
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55
Analysts' Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Entrada Therapeutics Inc (TRDA)
Zenas BioPharma (ZBIO) Stock Forum
$Zenas BioPharma (ZBIO.US)$ . Reuters
1m
Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine! Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints
1m
Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine! Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints
2
$Zenas BioPharma (ZBIO.US)$
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
by Globe Newswire
Follow
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -
- Obexelimab significantly lowered the total amount of glucocorticoid use and reduced g...
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
by Globe Newswire
Follow
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results -
- Obexelimab significantly lowered the total amount of glucocorticoid use and reduced g...
1
1
$Zenas BioPharma (ZBIO.US)$ZBIO (Zivo Bioscience): Director Patricia Allen executed multiple purchases totaling 19,860 shares across $24-$26 range (aggregate ~$400K), while Director Hongbo Lu bought 25,985 shares at $22.50 ($584,662).
4
$Zenas BioPharma (ZBIO.US)$this where it begins to fly.
$Zenas BioPharma Inc. ($Zbio) just cured lung cancer has price target of 200+ holy shit hurry and 😨😨😨😨👀👀👀🚀🚀🚀🚀🚀🚀🚀🚀
Zenas BioPharma Announces Groundbreaking Results from Pivotal Phase 3 Trial of Obexelimib in Advanced Non-Small Cell Lung Cancer (NSCLC)
Primary and all secondary endpoints met with unprecedented statistical significance; data suggests a potential functional cure for a majority of patients.
WALTHAM, Mass., January 7, 2026 – Zenas BioPharma (NASDAQ: ZNAS), a global biopharmaceuti...
Zenas BioPharma Announces Groundbreaking Results from Pivotal Phase 3 Trial of Obexelimib in Advanced Non-Small Cell Lung Cancer (NSCLC)
Primary and all secondary endpoints met with unprecedented statistical significance; data suggests a potential functional cure for a majority of patients.
WALTHAM, Mass., January 7, 2026 – Zenas BioPharma (NASDAQ: ZNAS), a global biopharmaceuti...
3
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)
dietpepsi : adding to watch list?
Trytosaveabit OP dietpepsi : yes! added to Watchlist